<ul>
<li>魔法蘑菇，現金流：Compass Pathways 的試驗勝利，快速融資</li>
</ul>
<p>Compass Pathways PLC 贊助的 ADR (NASDAQ:CMPS - 免費報告) - HC Wainwright 的投資分析師在 3 月 2 日星期一發布的報告中對 Compass Pathways 的 2030 財年每股收益進行了估計。HC Wainwright 分析師 P. Trucchio 預測該公司在這一年將每股賺取 6.46 美元。HC Wainwright 目前對該股票給予 &#34;買入&#34; 評級，目標價為 70.00 美元。市場普遍預計 Compass Pathways 當前全年的每股收益為（-2.33 美元）。</p>
<p>獲取 <strong>Compass Pathways</strong> 的提醒：</p>
<p>其他研究分析師也對該公司發佈了報告。摩根士丹利在 2 月 18 日星期三的研究報告中將 Compass Pathways 的目標價從 11.00 美元上調至 18.00 美元，並給予該公司 &#34;超配&#34; 評級。Compass Point 在 2 月 12 日星期四的研究報告中設定了 Compass Pathways 的 15.00 美元目標價。Lifesci Capital 在 2 月 12 日星期四的報告中將 Compass Pathways 的評級上調至 &#34;強力買入&#34;。Weiss Ratings 在 1 月 21 日星期三的報告中重新發布了對 Compass Pathways 股票的 &#34;賣出（d-）&#34; 評級。最後，加拿大皇家銀行在 2 月 18 日星期三的研究報告中將 Compass Pathways 股票的目標價從 21.00 美元上調至 22.00 美元，並給予該公司 &#34;跑贏大盤&#34; 評級。一位投資分析師對該股票給予了強力買入評級，六位給予了買入評級，一位給予了持有評級，一位給予了賣出評級。根據 MarketBeat 的數據，該股票目前的共識評級為 &#34;適度買入&#34;，平均目標價為 22.13 美元。</p>
<p><strong>閲讀我們關於 Compass Pathways 的最新報告</strong></p>
<h2>Compass Pathways 股票表現</h2>
<p>Compass Pathways 股票在星期三開盤價為 6.95 美元。該公司的債務與股本比率為 0.55，流動比率為 1.23，速動比率為 1.23。該公司的 50 日簡單移動平均為 6.98 美元，200 日簡單移動平均為 6.12 美元。Compass Pathways 的 52 周低點為 2.25 美元，52 周高點為 8.90 美元。該公司的市值為 6.6734 億美元，市盈率為 -2.56，貝塔值為 1.90。</p>
<h2>對 Compass Pathways 的對沖基金看法</h2>
<p>幾家對沖基金和其他機構投資者最近對 CMPS 的持倉進行了調整。Persistent Asset Partners Ltd 在第四季度新建了對 Compass Pathways 的持倉，價值約 38,000 美元。Advisory Services Network LLC 在第三季度新購入了價值約 41,000 美元的 Compass Pathways 股票。Caitong International Asset Management Co. Ltd 在第四季度新購入了價值約 47,000 美元的 Compass Pathways 股票。China Universal Asset Management Co. Ltd. 在第二季度將其在 Compass Pathways 的持股增加了 46.7%。China Universal Asset Management Co. Ltd. 目前擁有該公司 18,272 股股票，價值 51,000 美元，此前在上個季度又購入了 5,817 股。最後，BIT Capital GmbH 在第三季度新購入了價值約 54,000 美元的 Compass Pathways 股票。46.19% 的股票由機構投資者持有。</p>
<h2>Compass Pathways 公司簡介</h2>
<p>（獲取免費報告）</p>
<p>Compass Pathways NASDAQ: CMPS 是一家臨牀階段的生物技術公司，專注於開發和商業化用於心理健康障礙的迷幻蘑菇療法。該公司成立於 2016 年，總部位於倫敦，並在美國設有其他辦事處，正在開創將合成迷幻蘑菇與心理治療結合使用以應對難治性抑鬱症的先河。該公司的旗艦項目是一個 IIb 期臨牀試驗，評估其專有的迷幻蘑菇配方 COMP360，該配方已獲得美國的突破性療法認證。</p>
<h2>瞭解更多</h2>
<ul>
<li>我們更看好的五隻股票比 Compass Pathways 更好</li>
<li>新發現富銅的 “克拉肯” 區</li>
<li>美國的 1776 再次發生</li>
<li>你可能想更換財務顧問的 3 個跡象</li>
<li>股票代碼揭曉：預 IPO 獲取 “下一個埃隆·馬斯克” 公司的機會</li>
<li>白銀的擠壓正在加緊 - 機會正在形成</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/EarningsEstimatesChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9Q01QUw?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/EarningsEstimatesChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9Q01QUw"/></p>
<p><em>此即時新聞提醒由敍事科學技術和 MarketBeat 的金融數據生成，以便為讀者提供最快的報道和公正的覆蓋。如對本故事有任何問題或意見，請發送郵件至 contact@marketbeat.com。</em></p>
<h2>你現在應該投資 1,000 美元在 Compass Pathways 嗎？</h2>
<p>在你考慮 Compass Pathways 之前，你需要聽聽這個。</p>
<p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其推薦給客户的股票。MarketBeat 已識別出五隻股票，頂級分析師正在悄悄地向客户推薦，現在就買入，以便在更廣泛的市場注意到之前... 而 Compass Pathways 並不在名單上。</p>
<p>雖然 Compass Pathways 目前在分析師中獲得了適度買入評級，但頂級分析師認為這五隻股票更值得買入。</p>
<p>在這裏查看這五隻股票</p>

CMPS

<p>HC Wainwright 分析師預測，Compass Pathways PLC（NASDAQ:CMPS）在 2030 財年每股收益將達到 6.46 美元，維持 “買入” 評級，目標價為 70 美元。其他分析師的評級和目標價各不相同，普遍評級為 “適度買入”，平均目標價為 22.13 美元。該股票開盤價為 6.95 美元，市值為 6.6734 億美元。Compass Pathways 專注於用於心理健康障礙的迷幻蘑菇治療，目前正在進行其專有配方 COMP360 的 IIb 期臨牀試驗</p>

<ul>
<li>Magic Mushrooms, Hard Cash: Compass Pathways’ Trial Win, Fast Raise</li>
</ul>
<div class="lb-trans"><ul>
<li>魔法蘑菇，現金流：Compass Pathways 的試驗勝利，快速融資</li>
</ul>
</div><p>Compass Pathways PLC Sponsored ADR (NASDAQ:CMPS - Free Report) - Investment analysts at HC Wainwright issued their FY2030 earnings per share estimates for Compass Pathways in a report issued on Monday, March 2nd. HC Wainwright analyst P. Trucchio forecasts that the company will earn $6.46 per share for the year. HC Wainwright currently has a &#34;Buy&#34; rating and a $70.00 target price on the stock. The consensus estimate for Compass Pathways' current full-year earnings is ($2.33) per share.</p>
<div class="lb-trans"><p>Compass Pathways PLC 贊助的 ADR (NASDAQ:CMPS - 免費報告) - HC Wainwright 的投資分析師在 3 月 2 日星期一發布的報告中對 Compass Pathways 的 2030 財年每股收益進行了估計。HC Wainwright 分析師 P. Trucchio 預測該公司在這一年將每股賺取 6.46 美元。HC Wainwright 目前對該股票給予 &#34;買入&#34; 評級，目標價為 70.00 美元。市場普遍預計 Compass Pathways 當前全年的每股收益為（-2.33 美元）。</p>
</div><p>Get <strong>Compass Pathways</strong> alerts:</p>
<div class="lb-trans"><p>獲取 <strong>Compass Pathways</strong> 的提醒：</p>
</div><p>Other research analysts have also issued reports about the company. Morgan Stanley increased their price objective on Compass Pathways from $11.00 to $18.00 and gave the company an &#34;overweight&#34; rating in a research report on Wednesday, February 18th. Compass Point set a $15.00 price target on Compass Pathways in a research note on Thursday, February 12th. Lifesci Capital upgraded Compass Pathways to a &#34;strong-buy&#34; rating in a report on Thursday, February 12th. Weiss Ratings reissued a &#34;sell (d-)&#34; rating on shares of Compass Pathways in a report on Wednesday, January 21st. Finally, Royal Bank Of Canada upped their target price on shares of Compass Pathways from $21.00 to $22.00 and gave the company an &#34;outperform&#34; rating in a research report on Wednesday, February 18th. One investment analyst has rated the stock with a Strong Buy rating, six have given a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat, the stock currently has a consensus rating of &#34;Moderate Buy&#34; and an average target price of $22.13.</p>
<div class="lb-trans"><p>其他研究分析師也對該公司發佈了報告。摩根士丹利在 2 月 18 日星期三的研究報告中將 Compass Pathways 的目標價從 11.00 美元上調至 18.00 美元，並給予該公司 &#34;超配&#34; 評級。Compass Point 在 2 月 12 日星期四的研究報告中設定了 Compass Pathways 的 15.00 美元目標價。Lifesci Capital 在 2 月 12 日星期四的報告中將 Compass Pathways 的評級上調至 &#34;強力買入&#34;。Weiss Ratings 在 1 月 21 日星期三的報告中重新發布了對 Compass Pathways 股票的 &#34;賣出（d-）&#34; 評級。最後，加拿大皇家銀行在 2 月 18 日星期三的研究報告中將 Compass Pathways 股票的目標價從 21.00 美元上調至 22.00 美元，並給予該公司 &#34;跑贏大盤&#34; 評級。一位投資分析師對該股票給予了強力買入評級，六位給予了買入評級，一位給予了持有評級，一位給予了賣出評級。根據 MarketBeat 的數據，該股票目前的共識評級為 &#34;適度買入&#34;，平均目標價為 22.13 美元。</p>
</div><p><strong>Read Our Latest Report on Compass Pathways</strong></p>
<div class="lb-trans"><p><strong>閲讀我們關於 Compass Pathways 的最新報告</strong></p>
</div><h2>Compass Pathways Stock Performance</h2>
<div class="lb-trans"><h2>Compass Pathways 股票表現</h2>
</div><p>Shares of Compass Pathways stock opened at $6.95 on Wednesday. The company has a debt-to-equity ratio of 0.55, a current ratio of 1.23 and a quick ratio of 1.23. The firm has a 50 day simple moving average of $6.98 and a 200 day simple moving average of $6.12. Compass Pathways has a fifty-two week low of $2.25 and a fifty-two week high of $8.90. The firm has a market cap of $667.34 million, a P/E ratio of -2.56 and a beta of 1.90.</p>
<div class="lb-trans"><p>Compass Pathways 股票在星期三開盤價為 6.95 美元。該公司的債務與股本比率為 0.55，流動比率為 1.23，速動比率為 1.23。該公司的 50 日簡單移動平均為 6.98 美元，200 日簡單移動平均為 6.12 美元。Compass Pathways 的 52 周低點為 2.25 美元，52 周高點為 8.90 美元。該公司的市值為 6.6734 億美元，市盈率為 -2.56，貝塔值為 1.90。</p>
</div><h2>Hedge Funds Weigh In On Compass Pathways</h2>
<div class="lb-trans"><h2>對 Compass Pathways 的對沖基金看法</h2>
</div><p>Several hedge funds and other institutional investors have recently made changes to their positions in CMPS. Persistent Asset Partners Ltd acquired a new position in Compass Pathways during the fourth quarter worth approximately $38,000. Advisory Services Network LLC acquired a new stake in shares of Compass Pathways in the third quarter valued at approximately $41,000. Caitong International Asset Management Co. Ltd bought a new position in shares of Compass Pathways during the 4th quarter worth approximately $47,000. China Universal Asset Management Co. Ltd. increased its holdings in shares of Compass Pathways by 46.7% during the 2nd quarter. China Universal Asset Management Co. Ltd. now owns 18,272 shares of the company's stock worth $51,000 after acquiring an additional 5,817 shares during the last quarter. Finally, BIT Capital GmbH acquired a new position in shares of Compass Pathways during the 3rd quarter worth approximately $54,000. 46.19% of the stock is owned by institutional investors.</p>
<div class="lb-trans"><p>幾家對沖基金和其他機構投資者最近對 CMPS 的持倉進行了調整。Persistent Asset Partners Ltd 在第四季度新建了對 Compass Pathways 的持倉，價值約 38,000 美元。Advisory Services Network LLC 在第三季度新購入了價值約 41,000 美元的 Compass Pathways 股票。Caitong International Asset Management Co. Ltd 在第四季度新購入了價值約 47,000 美元的 Compass Pathways 股票。China Universal Asset Management Co. Ltd. 在第二季度將其在 Compass Pathways 的持股增加了 46.7%。China Universal Asset Management Co. Ltd. 目前擁有該公司 18,272 股股票，價值 51,000 美元，此前在上個季度又購入了 5,817 股。最後，BIT Capital GmbH 在第三季度新購入了價值約 54,000 美元的 Compass Pathways 股票。46.19% 的股票由機構投資者持有。</p>
</div><h2>Compass Pathways Company Profile</h2>
<div class="lb-trans"><h2>Compass Pathways 公司簡介</h2>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>（獲取免費報告）</p>
</div><p>Compass Pathways NASDAQ: CMPS is a clinical-stage biotechnology company focused on the development and commercialization of psilocybin therapy for mental health disorders. Founded in 2016 and headquartered in London with additional offices in the United States, Compass Pathways is pioneering the use of synthetic psilocybin combined with psychotherapy to address treatment-resistant depression. The company’s flagship program is a Phase IIb clinical trial evaluating COMP360, its proprietary psilocybin formulation, which has received Breakthrough Therapy designation from the U.S.</p>
<div class="lb-trans"><p>Compass Pathways NASDAQ: CMPS 是一家臨牀階段的生物技術公司，專注於開發和商業化用於心理健康障礙的迷幻蘑菇療法。該公司成立於 2016 年，總部位於倫敦，並在美國設有其他辦事處，正在開創將合成迷幻蘑菇與心理治療結合使用以應對難治性抑鬱症的先河。該公司的旗艦項目是一個 IIb 期臨牀試驗，評估其專有的迷幻蘑菇配方 COMP360，該配方已獲得美國的突破性療法認證。</p>
</div><h2>Read More</h2>
<div class="lb-trans"><h2>瞭解更多</h2>
</div><ul>
<li>Five stocks we like better than Compass Pathways</li>
<li>New Copper-Rich “Kraken” Zone Discovered</li>
<li>America’s 1776 happening again</li>
<li>3 Signs You May Want to Switch Financial Advisors</li>
<li>Ticker Revealed: Pre-IPO Access to &#34;Next Elon Musk&#34; Company</li>
<li>Silver's squeeze is tightening - opportunity forming</li>
</ul>
<div class="lb-trans"><ul>
<li>我們更看好的五隻股票比 Compass Pathways 更好</li>
<li>新發現富銅的 “克拉肯” 區</li>
<li>美國的 1776 再次發生</li>
<li>你可能想更換財務顧問的 3 個跡象</li>
<li>股票代碼揭曉：預 IPO 獲取 “下一個埃隆·馬斯克” 公司的機會</li>
<li>白銀的擠壓正在加緊 - 機會正在形成</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/EarningsEstimatesChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9Q01QUw" alt="" original-src="https://www.marketbeat.com/scripts/EarningsEstimatesChart.ashx?Prefix=NASDAQ&amp;Symbol=CMPS"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即時新聞提醒由敍事科學技術和 MarketBeat 的金融數據生成，以便為讀者提供最快的報道和公正的覆蓋。如對本故事有任何問題或意見，請發送郵件至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in Compass Pathways Right Now?</h2>
<div class="lb-trans"><h2>你現在應該投資 1,000 美元在 Compass Pathways 嗎？</h2>
</div><p>Before you consider Compass Pathways, you'll want to hear this.</p>
<div class="lb-trans"><p>在你考慮 Compass Pathways 之前，你需要聽聽這個。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Compass Pathways wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其推薦給客户的股票。MarketBeat 已識別出五隻股票，頂級分析師正在悄悄地向客户推薦，現在就買入，以便在更廣泛的市場注意到之前... 而 Compass Pathways 並不在名單上。</p>
</div><p>While Compass Pathways currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>雖然 Compass Pathways 目前在分析師中獲得了適度買入評級，但頂級分析師認為這五隻股票更值得買入。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在這裏查看這五隻股票</p>
</div>

HC Wainwright 發佈的 Compass Pathways 2030 財年收益預測